Letters

Inequality in funding for AIDS across England threatens regional services

BMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7113.950a (Published 11 October 1997) Cite this as: BMJ 1997;315:950
  1. Mark A Bellis, Senior lecturera,
  2. Joanne McCullagh, Research associatea,
  3. Roderick Thomson, Public health projects coordinatorb,
  4. David Regan, Public health specialistc,
  5. Qutub Syed, Regional epidemiologistd,
  6. Terry Kelly, Joint commissioning managere
  1. a Sexual Health and Environmental Epidemiology Unit, Department of Public Health, University of Liverpool, Liverpool L69 3GB
  2. b Sefton Health Authority, Liverpool L22 0QB
  3. c Manchester Health Authority, Manchester M60 7PL
  4. d Communicable Disease Surveillance Centre (North West), Public Health Laboratory, Liverpool L9 7AL
  5. e Liverpool Health Authority, Liverpool L3 6AL

    Editor—Recent developments in antiretroviral treatment offer the potential for substantial progress in the management of patients infected with HIV.1 A series of trials have now shown that combination treatments with antiretroviral drugs offer significantly better prospects to patients than the use of monotreatment with nucleoside analogues such as zidovudine.2 In addition, limited evidence suggests that triple treatments, incorporating protease inhibitors, produce further substantial reductions in viral loads and may almost entirely eliminate the virus.3 Monotreatments have proved too costly …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe